Lakeside Cancer Center will connect cancer patients in the Glades with world-class treatment, complex care coordination and ...

First PATHFINDER 2 Results Accepted as a Late-Breaking Presentation at the European Society for Medical Oncology (ESMO) ...

TEVIMBRA plus ZIIHERA and chemotherapy significantly improved progression-free survival (PFS) versus trastuzumab plus ...

Daridorexant, a dual orexin receptor antagonist, is the first investigational treatment in its class to demonstrate positive ...

Pathos AI, Inc., a clinical-stage AI and technology company advancing its own therapeutic pipeline of drugs, today announced ...

Peer-reviewed study demonstrates potent, multi-month extrahepatic delivery via both systemic administration—targeting ...

XBiotech Inc. (NASDAQ: XBIT) today announced that its Board of Directors have elected Jan-Paul Simard to serve as Co-Chief ...

(NASDAQ: TEM, “Tempus”) today announced a multi-year agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”), under which BMS ...

Company to participate in TCT for the first time as the ALARA+ consensus statement elevates industry focus on occupational ...

Presentations showcase AI-powered multimodal analytics that unblind tumor biology and accelerate drug development. WALTHAM, ...

Remibrutinib achieved significant and clinically meaningful reduction in relapses vs. teriflunomide, to approximately 1 ...

Bristol Myers Squibb (NYSE: BMY) today announced disclosure of interim safety and efficacy results from the multiple ...